专注于慢性乙型肝炎病毒（HBV）感染治疗的生物技术公司Aligos Therapeutics, Inc.，近日宣布已收到一笔高达2500万美元的首付款。这笔款项源自其与合作伙伴就创新药物Pevifoscorvir Sodium（一款针对慢性HBV感染的候选药物）在大中华区达成的独家许可协议。该协议标志着Aligos Therapeutics在拓展关键亚洲市场方面迈出了重要一步，有望为众多慢性乙肝患者带来新的治疗选择。
专注于慢性乙型肝炎病毒（HBV）感染治疗的生物技术公司Aligos Therapeutics, Inc.，近日宣布已收到一笔高达2500万美元的首付款。这笔款项源自其与合作伙伴就创新药物Pevifoscorvir Sodium（一款针对慢性HBV感染的候选药物）在大中华区达成的独家许可协议。该协议标志着Aligos Therapeutics在拓展关键亚洲市场方面迈出了重要一步，有望为众多慢性乙肝患者带来新的治疗选择。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.